Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Insider sale notice for Arcutis Biotherapeutics, Inc. (ARQT). The filer reports a proposed sale of 10,000 common shares via Merrill (Columbus, OH) with an aggregate market value of $156,083 and an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired by stock option exercise on 03/13/2019 and payment is listed as cash. The filing also discloses three sales by Howard Welgus totaling 29,347 shares during June–August 2025, generating gross proceeds of $405,406 combined. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold company common stock in two reported transactions under a 10b5-1 plan and to cover tax withholding on vested performance-based restricted stock units. On 08/19/2025 he sold 1,750 shares at a weighted average price of $16.1604, leaving him with 107,249 shares beneficially owned. On 08/21/2025 he sold 2,438 shares at a weighted average price of $15.5738, leaving him with 104,811 shares beneficially owned.
The filing notes the 08/21 trades were effected pursuant to a 10b5-1 trading plan adopted December 12, 2024 (plan end date February 27, 2026). The 08/19 sale was to cover tax withholding on vested performance-based RSUs. Sales occurred in multiple transactions at noted price ranges and the reporting person offers to provide detailed per-trade allocations on request.
Form 144 notice for Arcutis Biotherapeutics, Inc. (ARQT) reports a proposed sale of 2,438 common shares with an aggregate market value of $37,969, against ~119,905,078 shares outstanding. The shares were acquired on 08/18/2025 via restricted stock vesting and the planned sale date is 08/21/2025 through Merrill Lynch on NASDAQ. The filer, identified elsewhere in the form, has completed multiple sales in the prior three months totaling 36,969 shares for gross proceeds of $369,869, indicating ongoing disposition of personal holdings rather than a single large block sale.
Frazier-affiliated investment funds and principals reported holdings in Arcutis Biotherapeutics, Inc. common stock on Schedule 13D/A. Frazier Life Sciences VIII, L.P. directly holds 8,785,284 shares (about 7.3% of the 119,905,078 shares outstanding), and related Frazier entities and principals together report beneficial positions that result in individual aggregates such as 8,843,386 shares for James N. Topper and 8,943,712 shares for Patrick J. Heron (each roughly 7.4–7.5% of the class as reported). The filing states these holdings were acquired for investment purposes, with working capital used as the source of funds for certain purchases. The reporting persons disclose that, except as set forth, they have no present plans to pursue control transactions, board changes, material asset sales, charter amendments, delisting, or similar corporate actions. The Schedule 13D/A updates ownership tables, clarifies sources of funds, and incorporates prior amendments and agreements among the filing entities.
Form 144 filed for Arcutis Biotherapeutics, Inc. (ARQT) discloses a proposed sale of 1,750 common shares through Merrill Lynch on 08/19/2025. The shares were acquired by restricted stock vesting on 08/18/2025. The filer lists four recent sales by Patrick Burnett within the past three months totaling 33,219 shares for aggregate gross proceeds of $521,160.00 (sales on 07/10/2025, 07/14/2025, 08/04/2025, and 08/08/2025). The notice affirms the filer is not aware of undisclosed material adverse information and includes the standard attestation about trading plans and criminal penalties for misstatement.
Polar Capital reports beneficial ownership of 5,006,472 shares of Arcutis Biotherapeutics common stock, representing 4.2% of the class based on 119,201,724 shares outstanding. The filing identifies three reporting persons — Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund — and classifies their roles as a holding company, an investment adviser and a fund.
All reported shares are held with sole voting and sole dispositive power. The filer certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control. This Schedule 13G/A reflects a passive disclosed stake below the 5% threshold.
Arcutis Biotherapeutics executive Patrick Burnett, the company's Executive Vice President and Chief Medical Officer, sold 3,847 shares of Arcutis common stock on 08/08/2025. The sales were made pursuant to a 10b5-1 trading plan adopted on 12/12/2024 with a plan end date of 02/27/2026. The filing reports a weighted-average sale price of $14.0339, with individual trade prices ranging from $13.992 to $14.12. After the reported transaction, Burnett directly beneficially owned 108,999 shares.
Arcutis Biotherapeutics filed a Form 144 disclosing a proposed sale of 41,979 shares of common stock to be executed through Merrill with an aggregate market value of $611,936. The filing lists the approximate sale date as 08/08/2025 and records total shares outstanding of 119,201,724. The securities were acquired from Arcutis by stock option exercise on 04/10/2024 and are described as shares to be delivered on the stated sale date.
The filing also shows a recent sale in the prior three months: 53,187 shares sold on 08/06/2025 for gross proceeds of $797,466 (seller named as David Topper). The notice includes the standard attestation that the person for whose account the shares will be sold does not possess undisclosed material adverse information about the issuer.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a planned sale of 3,847 common shares to be executed through Merrill Lynch on 08/08/2025. The filing shows these shares were acquired on 08/01/2025 as a restricted stock vest from Arcutis Biotherapeutics, Inc., and lists an aggregate market value of $53,988.51 and the company’s outstanding shares as 119,201,724. The trade is slated for NASDAQ.
The filing also discloses recent sales by Patrick Burnett in the past three months: 23,000 shares on 07/10/2025 for $346,047.00, 5,750 shares on 07/14/2025 for $86,654.00, and 2,622 shares on 08/04/2025 for $37,485.69. No additional commentary or plan-adoption date is provided in the form text.